Ethereum plans to activate the Glamsterdam upgrade on its Sepolia testnet on October 6, marking a key step in testing protocol changes aimed at increasing Layer 1 capacity and processing efficiency. The upgrade combines the Amsterdam execution-layer and Gloas consensus-layer improvements, introducing features like proposer-builder separation (ePBS) and block-level access lists (BALs) to speed up transaction processing and reduce reliance on third-party infrastructure. These changes could triple Ethereum's base throughput and expand block propagation time, with a mainnet rollout expected in late 2026 but no fixed date yet. This testnet activation is part of ongoing efforts following previous upgrades and extensive testing on devnets and public testnets.
Ethereum's upcoming Sepolia fork for the Glamsterdam upgrade is noted here with Pluang's market snapshot as of Sep 30, 2026 01:02 WIB: Among 50 major cryptocurrencies priced on Pluang, 15 rose and 34 fell today. Notable movers include CRV (Curve DAO Token) at Rp6.764 with a 1-day change of +8.59%, EOS (EOS.IO) at Rp12.649 with +8.13%, and ALGO (Algorand) at Rp2.240 down -8.72%.
Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...
Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...
Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...
uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...
Altrova Health Inc. has settled C$215,000 of outstanding debt by issuing 3,583,333 common shares at a price of C$0.06 per share to three creditors. This debt settlement did not bring in cash but helped reduce the company's liabilities and preserve ca...
